Showing results for "Drugs" in Biological Sciences

Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing - atom by atom - both a new life-saving immunosuppressant drug and a drug to combat the virus that causes AIDS.

Despite advances in health care, infectious microbes continue to be a formidable adversary to scientists and doctors. Vaccines and antibiotics, the mainstays of modern medicine, have not been able to conquer infectious microbes because of their amazing ability to adapt, evolve, and spread to new places. Terrorism aside, one of the greatest dangers from infectious disease we face today is from a massive outbreak of drug-resistant microbes.

Is there a pill for love? What about an "anti-love drug", to help us get over an ex? This book argues that certain psychoactive substances, including MDMA - the active ingredient in Ecstasy - may help ordinary couples work through relationship difficulties and strengthen their connection. Others may help sever an emotional connection during a breakup. These substances already exist, and they have transformative implications for how we think about love.

Welcome to "Drug Diaries," the podcast exploring pharmaceuticals, life sciences, and biotechnology. Host Kaushik Trivedi, with over two decades of industry experience, shares his expertise. Kaushik has worked with IQVIA, Cognizant, Wipro, and more, and holds degrees in pharmaceutical chemistry, marketing, and advertising. Kaushik's expertise spans: - Data-Driven GTM & Customer Engagement - CRM, Marketing Cloud, SFE, & Commercial Analytics - AI/ML/NLP in Life Sciences - Population Health Management - IoT & Connected Devices - Content Production & MLR Approval - R&D, Clinical, Pharmacovigilance,...

Welcome to Conversations in Drug Development, brought to you by the team at Boyds for our fellow community of scientists and clinicians working in the wonderful world of cell and gene therapy and drug development. This podcast series features candid conversations from the expert team at Boyds, who are at the forefront of cutting-edge science and drug development in the pharmaceutical and biotechnology sector.

Transcribed from the original lectures recorded at San Francisco State University in 1987, The Nature of Drugs series highlights Shulgin’s engaging lecture style peppered with illuminating anecdotes and amusing asides. Ostensibly taught as an introductory course on drugs and biochemistry, these books serve as both a historical record of Shulgin’s teaching style and the culmination of his philosophy on drugs, psychopharmacology, states of consciousness, and societal and individual freedoms pertaining to their use, both medicinal and exploratory.

A renowned neuroscientist provides an “unorthodox but enlightening” (Wall Street Journal) narrative of how addiction happens in the brain, and what we can do to overcome it Through the vivid, true stories of five people who journeyed into and out of addiction, a renowned neuroscientist—and...

The introduction of new medicines has dramatically improved the quantity and quality of individual and public health, while contributing trillions of dollars to the global economy. In spite of these past successes - and indeed because of them - our ability to deliver new medicines may be quickly coming to an end. Moving from the 20th century to the present, A Prescription for Change reveals how changing business strategies combined with scientific hubris have altered the way new medicines are discovered, with dire implications for both health and the economy.

From one of the world's foremost experts on the subject, a powerful argument that the greatest damage from drugs flows from their being illegal, and a hopeful reckoning with the possibility of their use as part of a responsible and happy life Dr. Carl L. Hart, Ziff Professor at Columbia...

Ever wondered what's really happening behind the scenes in the biotech and pharmaceutical industry? Drug Dealin' pulls back the curtain. Co-hosts Shivu Sharma and Kenny Lalwani, two seasoned BioPharma professionals, offer unparalleled insider insights, dissecting the latest news, trends, and catalysts. Each episode features in-depth discussions and interviews with industry luminaries, giving you honest and unvarnished perspectives you won't find anywhere else.

In this series, we discuss the evolving landscape of obesity drug development, exploring the science, patient experiences, and clinical trial innovations that are shaping a new era in care. Through candid conversations with advocates like Sarah Le Brocq and expert insights from host Claudia Filozof, the podcast examines obesity as a complex, chronic disease—challenging stigma, highlighting the importance of empathy in healthcare, and advocating for patient-centric approaches in clinical research.

The most popular drug in America is a white powder. No, not that powder. This is caffeine in its most essential state. And Caffeinated reveals the little-known truth about this addictive, largely unregulated drug found in coffee, energy drinks, teas, colas, chocolate, and even pain relievers. Drawing on the latest research, Caffeinated brings us the inside perspective at the additive that Salt Sugar Fat overlooked.

Jim Geraghty has been a passionate participant in the orphan drug revolution since its inception―a leader in the field as a strategy consultant, biotechnology executive, and venture entrepreneur. His book is in part a history, with eyewitness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen. And it tells deeply personal stories of patients and parents willing to risk untried new therapies.

Do antidepressants work, or are they no better than placebos? Like his colleagues, Irving Kirsch spent years referring patients to psychiatrists to have their depression treated with drugs. Eventually, however, he decided to investigate for himself just how effective the drugs actually were. With 15 years of research, Kirsch demonstrates that what everyone “knew” about antidepressants is wrong; what the medical community considered a cornerstone of psychiatric treatment is little more than a faulty consensus.

Drug Safety Matters brings you the best stories from the world of pharmacovigilance. Through in-depth interviews with our guests, we cover new research and trends, and explore the most pressing issues in medicines safety today. Produced by Uppsala Monitoring Centre, the WHO Collaborating Centre for International Drug Monitoring. The views and opinions expressed in the podcast are those of the hosts and guests respectively and, unless otherwise stated, do not represent the position of any institution to which they are affiliated.

Explore Cannabinoid and Psychedelic Pharmacology with AI-Powered Learning.Welcome to a groundbreaking approach to mastering cannabinoid and psychedelic pharmacology and the FDA drug development pathway! This podcast series, powered by Google’s Notebook LM, offers a cutting-edge, AI-guided learning experience tailored for formal classes or self-directed study.Each 30-day series delves deep into the science of cannabinoid and psychedelic pharmacology, exploring molecular signaling pathways, therapeutic applications, and regulatory challenges. Using a spiraling learning approach, foundational ...

QCast by Quanticate is the podcast for biotech, pharma, and life science leaders looking to deepen their understanding of biometrics and modern drug development. Join co-hosts Tom and Jullia as they explore methodologies, case studies, regulatory shifts, and industry trends shaping the future of clinical research. Where biometric expertise meets data-driven dialogue, QCast delivers practical insights and thought leadership to inform your next breakthrough.

Many medical devices and prescription drugs claim to be the resolution to all your problems, but while they may solve your current issue, it's possible they may cause another. Medical products are often rushed to market before they're adequately tested. Clay Hodges wants to educate you on these products and their side effects before they lead to litigation.

Readings of weekly drug cards based on the NREMT curriculum.

DDN Dialogues is a new podcast from Drug Discovery News. Join us as we explore the stories behind the latest advances in drug discovery research.